PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01696565

Recruitment Status : Completed

First Posted : October 1, 2012

Last Update Posted : April 1, 2021

Sponsor:

Information provided by (Responsible Party):

PhytoHealth Corporation

Study Description

Brief Summary:

The objectives of this Phase I/II study are:

To find out the maximum tolerated dose (MTD) of PG2 in patients with advanced malignancy receiving chemotherapy and to define a "Study Dose" for Phase II.
To evaluate the hematopoietic and immunological responses after administering of PG2. Primarily to study the biological response of PG2, defined as WBC count in this study, and secondarily to study the immunological factors, IL-2, IL-6, TGF-beta, and G-CSF.

Condition or disease	Intervention/treatment	Phase
Neoplasm Metastasis Neoplasm Recurrence	Drug: PG2	Phase 1 Phase 2

Detailed Description:

This study is the first step for PG2 clinical development in Taiwan in order to further establish its safety and efficacy profile and to build the basis for larger trials.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	32 participants
Allocation:	Non-Randomized
Intervention Model:	Factorial Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy
Actual Study Start Date :	December 2001
Actual Primary Completion Date :	October 2003
Actual Study Completion Date :	October 2003

Arms and Interventions

Arm	Intervention/treatment
Experimental: 125 mg/day Treatment Arm 125 mg/day PG2 treatment continuously for 7 days	Drug: PG2 Injectable
Experimental: 250 mg/day Treatment Arm 250 mg/day PG2 treatment continuously for 7 days	Drug: PG2 Injectable
Experimental: 500 mg/day Treatment Arm 500 mg/day PG2 treatment continuously for 7 days	Drug: PG2 Injectable

Outcome Measures

Primary Outcome Measures :

Phase I: To find the maximum tolerated dose (MTD) or the highest tolerated dose (HTD) as the study dose of PG2; Phase II: To use the study dose and assess the WBC level of PG2 [ Time Frame: within 14 days of each chemotherapy cycle ]
For phase I study, the primary endpoint is to determine a safe dosage of PG2 by the dose escalation design.

For phase II study, the primary endpoint is to compare the WBC level between PG2 plus chemotherapy and chemotherapy alone.

Secondary Outcome Measures :

Phase II: To use the study dose to assess the hematopoietic and immunological cytokine levels [ Time Frame: within 14 days of each chemotherapy cycle ]
For phase II study, the secondary endpoint is to compare the levels of IL-2, IL-6, TGF-beta and G-CSF between PG2 plus chemotherapy and chemotherapy alone.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	20 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patient must have malignancy with metastatic or recurrent diseases.
Patient must have a minimum of thirteen days period elapsed from any previous chemotherapy or radiotherapy and all treatment-related toxicities subsided.
Patient must have at least 2 courses of chemotherapy treatment left, and a minimum of 13 days between the administration of the last dose of the chemotherapy with PG2 and the start of the next course of chemotherapy.
Performance status is 0-2 by ECOG scale.
Patient's compliance and geographic proximity that allow adequate follow up.
Adequate bone marrow function before the chemotherapy
Adequate liver and renal function before the chemotherapy
Written informed consent from patients
Woman with childbearing potential should use contraception method through the whole PG2 treatment course.
After the previous course of chemotherapy, the nadir of WBC dropped between 1000 to 3000/ mm3 (for phase II only).

Exclusion Criteria:

PG2 skin test is positive.
Active infection
Breast feeding
Prior radiotherapy more than 30% of the bone marrow involved.
Pregnant woman
Bone marrow transplantation or brain disease

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01696565

Locations

Layout table for location information

Taiwan
Tri-Service General Hospital
Taipei, Taiwan, 114

Sponsors and Collaborators

PhytoHealth Corporation

Investigators

Layout table for investigator information

Principal Investigator:	Woei-Yao Kao, Chief	Taichung Tzu Chi Hospital

More Information

Layout table for additonal information

Responsible Party:	PhytoHealth Corporation
ClinicalTrials.gov Identifier:	NCT01696565
Other Study ID Numbers:	PH-CP002-2
First Posted:	October 1, 2012 Key Record Dates
Last Update Posted:	April 1, 2021
Last Verified:	March 2021

Keywords provided by PhytoHealth Corporation:


myelosuppression chemotherapy Astragalus membranaceus hematopoietic response

Additional relevant MeSH terms:

Layout table for MeSH terms

Neoplasms Neoplasm Metastasis Recurrence	Neoplastic Processes Pathologic Processes Disease Attributes

To Top